Skip to main content
. Author manuscript; available in PMC: 2024 Aug 13.
Published in final edited form as: Nat Biomed Eng. 2023 Jul 10;8(2):132–148. doi: 10.1038/s41551-023-01058-6

Extended Data Fig. 4 |. Generation of various therapeutic immune cells by MAJESTIC.

Extended Data Fig. 4 |

a, Quantification of the HER2.CAR T cell viability. b, Quantification of HER2.CAR-positive CD8 T cells. c, Representative flow-cytometry plots of EGFRvIII.CAR-NK92 cells were produced via either the SB system or lentiviral transduction. d, Quantification of (c). e, Quantification of CD19.20.CAR T cells. f, Flow cytometry detection of CD19 and CD20 expression in NALM6-GL cells. g, Cytolysis analysis of NALM6-GL cancer cells that were co-cultured with lenti-CD19.20.CAR and AAV-SB-CD19.20.CAR T cells. Donor 2 and donor VP2 T cells were used in this figure.